Par Drugs Standalone June 2024 Net Sales at Rs 22.61 crore, down 1.43 percent Y-o-Y - Moneycontrol
| PAR Stock | 294.05 12.65 4.50% |
About 55% of Par Drugs' shareholders are presently thinking to get in. The analysis of overall sentiment of trading Par Drugs And stock suggests that some investors are interested at this time. The current market sentiment, together with Par Drugs' historical and current headlines, can help investors time the market. In addition, many technical investors use Par Drugs And stock news signals to limit their universe of possible portfolio assets.
Par Drugs stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Par daily returns and investor perception about the current price of Par Drugs And as well as its diversification or hedging effects on your existing portfolios.
Par |
Par Drugs Standalone June 2024 Net Sales at Rs 22.61 crore, down 1.43 percent Y-o-Y Moneycontrol
Read at news.google.com
 |
Par Drugs Fundamental Analysis
We analyze Par Drugs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Par Drugs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Par Drugs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Par Drugs is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Par Drugs And Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Par Drugs stock to make a market-neutral strategy. Peer analysis of Par Drugs could also be used in its relative valuation, which is a method of valuing Par Drugs by comparing valuation metrics with similar companies.
Peers
Par Drugs Related Equities
| PFC | Power Finance | 5.43 | ||||
| RELIANCE | Reliance Industries | 3.47 | ||||
| ONGC | Oil Natural | 1.42 | ||||
| IOC | Indian Oil | 1.23 | ||||
| HDFCBANK | HDFC Bank | 0.25 |
Complementary Tools for Par Stock analysis
When running Par Drugs' price analysis, check to measure Par Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Par Drugs is operating at the current time. Most of Par Drugs' value examination focuses on studying past and present price action to predict the probability of Par Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Par Drugs' price. Additionally, you may evaluate how the addition of Par Drugs to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |